永安药业（002365）5月19日主力资金净流入1.82亿元

Group 1 - The core viewpoint of the news is that Yong'an Pharmaceutical (002365) has experienced a significant stock price increase of 9.99% as of May 19, 2025, closing at 15.41 yuan, with a trading volume of 507,300 hands and a transaction amount of 767 million yuan [1] - The company reported a total operating revenue of 171 million yuan for Q1 2025, representing a year-on-year decrease of 12.96%, and a net profit attributable to shareholders of 4.37 million yuan, down 115.23% year-on-year [1] - The company's liquidity ratios are strong, with a current ratio of 5.289 and a quick ratio of 4.876, while the debt-to-asset ratio stands at 10.45% [1] Group 2 - Yong'an Pharmaceutical has made investments in 8 external companies and participated in 20 bidding projects, indicating active engagement in business expansion [2] - The company holds 3 trademark registrations and 39 patents, showcasing its commitment to intellectual property development [2] - Yong'an Pharmaceutical has obtained 278 administrative licenses, reflecting its compliance and operational capabilities within the industry [2]